Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized Study of TLK286 (Telcyta®) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5)
Brief Summary: The purpose of this research study is to determine if Telcyta® given in combination with liposomal doxorubicin is more effective than liposomal doxorubicin alone in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer that is refractory or resistant to platinum chemotherapy.


Options:
A: Arm Label: Telcyta + Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: Telcyta, Drug: Liposomal Doxorubicin | Arm Label: Liposomal Doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Intervention Type: DRUG; Name: Telcyta; Assigned to Arm(s): Telcyta + Liposomal Doxorubicin | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin, Telcyta + Liposomal Doxorubicin
B: Arm Label: Control Arm; Type: OTHER; Interventions: Biological: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin, Other: specialized pathology review (Germany only) | Arm Label: Research Arm; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Other: specialized pathology review (Germany only) | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Control Arm | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Control Arm, Research Arm | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Control Arm, Research Arm | Intervention Type: OTHER; Name: specialized pathology review (Germany only); Assigned to Arm(s): Control Arm, Research Arm
C: Arm Label: Mirvetuximab Soravtansine; Type: EXPERIMENTAL; Interventions: Drug: Mirvetuximab Soravtansine | Arm Label: Investigator's Choice (IC) Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Topotecan, Drug: Pegylated liposomal doxorubicin | Intervention Type: DRUG; Name: Mirvetuximab Soravtansine; Assigned to Arm(s): Mirvetuximab Soravtansine | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Investigator's Choice (IC) Chemotherapy | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Investigator's Choice (IC) Chemotherapy | Intervention Type: DRUG; Name: Pegylated liposomal doxorubicin; Assigned to Arm(s): Investigator's Choice (IC) Chemotherapy
D: Arm Label: Carboplatin and gemcitabine + bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Bevacizumab | Arm Label: Carboplatin and gemcitabine + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Carboplatin and gemcitabine + placebo

Answer: A